IL2 and neuroblastoma: Based on these results, Dinutuximab (anti-GD2 ch14.18 antibody) in combination with IL2 and GM-CSF was approved by the United States Food and Drug Administration (FDA) in 2015 for the treatment of high-risk neuroblastoma patients (180).